Sequence: STR-H16R8 (stearyl-(His)16-(Arg)8)
| Experiment Id | EXP001503 |
|---|---|
| Paper | Therapeutic potential of a cell penetrating peptide (CPP, NP1) mediated siRNA delivery: Evidence in |
| Peptide | NP1 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 6 µM |
| Rna Concentration | 100 nM |
| Mixing Ratio | MR 1/60 (siRNA/NP1; N/R≈60) |
| Formulation Format | noncovalent NP1/siRNA complex (nanoparticle) |
| Formulation Components | NP1 + VEGF-A siRNA (electrostatic complex) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro (2D) |
| Cell Lines Or Primary Cells | HCT 116 human colon cancer cells (2D monolayer) |
| Animal Model | |
| Administration Route | |
| Output Type | Gene knockdown (qRT-PCR, 48 h) |
| Output Value | ~72% VEGF mRNA knockdown |
| Output Units | |
| Output Notes | NP1-VEGF-siRNA complexes reduced VEGF mRNA by ~72% at 48 h in 2D cells (comparable to Lipofectamine 2000). |
| Toxicity Notes | |
| Curation Notes |